

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-0118; Docket 2017-0001; Sequence 2]

Information Collection; Statement of Witness, Standard Form 94

AGENCY: Federal Vehicle Policy
Division, General Services
Administration (GSA).

ACTION: Notice of a request for
comments regarding a reinstatement,
with change, to an OMB clearance.

SUMMARY: Under the provisions of the
Paperwork Reduction Act of 1995, GSA
has submitted to the Office of
Management and Budget (OMB) a
request to review and approve a
reinstatement, with change, to an
information collection requirement
concerning Standard Form 94,
Statement of Witness.

DATES: Submit comments on or before
December 1, 2017.

FOR FURTHER INFORMATION CONTACT: Ray
Wynter, Federal Vehicle Policy
Division, 202-501-3802, or via email at
ray.wynter@gsa.gov.

ADDRESSES: Submit comments
identified by Information Collection
3090-0118, Statement of Witness, SF
94, by any of the following methods:
Regulations.gov: <http://www.regulations.gov>.

- *Regulations.gov*: <http://www.regulations.gov>. Submit comments
via the Federal eRulemaking portal by
searching the OMB control number.
Select the link "Submit a Comment"
that corresponds with "Information
Collection 3090-0118, Statement of
Witness, SF 94." Follow the instructions
provided at the "Submit a Comment"
screen. Please include your name,
company name (if any), and
"Information Collection 3090-0118,
Statement of Witness, SF 94" on your
attached document.

- *Mail:* General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW.,
Washington, DC 20405. ATTN: Mr. Poe/
IC 3090-0118, Statement of Witness, SF
94.

Instructions: Please submit comments
only and cite Information Collection
3090-0118, Statement of Witness, SF
94, in all correspondence related to this
collection. Comments received generally
will be posted without change to <http://www.regulations.gov>, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two to three days after

submission to verify posting (except
allow 30 days for posting of comments
submitted by mail).

SUPPLEMENTARY INFORMATION:

A. Purpose

GSA is requesting that OMB review
and approve information collection,
3090-0118, Statement of Witness, SF
94. This form is used by all Federal
agencies to report accident information
involving U.S. Government motor
vehicles.

B. Annual Reporting Burden

Respondents: 874.

Responses per Respondent: 1.

Total Annual Responses: 874.

Hours per Response: .333.

Total Burden Hours: 291.

C. Public Comment

*Public comments are particularly
invited on:* Whether this collection of
information is necessary and whether it
will have practical utility; whether our
estimate of the public burden of this
collection of information is accurate,
and based on valid assumptions and
methodology; ways to enhance the
quality, utility, and clarity of the
information to be collected.

Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW., Washington, DC
20405, telephone 202-501-4755. Please
cite OMB Control No. 3090-0118,
Statement of Witness, SF 94, in all
correspondence.

Dated: September 26, 2017.

David A. Shive,

*Chief Information Officer, General Services
Administration.*

[FR Doc. 2017-20983 Filed 9-29-17; 8:45 am]

BILLING CODE 6820-43-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board), Subcommittee on Procedures Review (SPR), National Institute for Occupational Safety and Health (NIOSH)

AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with section
10(a)(2) of the Federal Advisory

Committee Act (Pub. L. 92-463), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting for the Subcommittee
on Procedures Review (SPR) of the
Advisory Board on Radiation and
Worker Health (ABRWH). This meeting
is open to the public, but without a
public comment period. The public is
welcome to submit written comments in
advance of the meeting, to the contact
person below. Written comments
received in advance of the meeting will
be included in the official record of the
meeting. The public is also welcome to
listen to the meeting by joining the
teleconference at the USA toll-free, dial-
in number at 1-866-659-0537; the pass
code is 9933701. The conference line
has 150 ports for callers.

DATES: The meeting will be held on
November 20, 2017, 11:00 a.m. to 4:30
p.m. ET.

ADDRESSES: Audio Conference Call via
FTS Conferencing. The USA toll-free
dial-in number is 1-866-659-0537; the
pass code is 9933701.

FOR FURTHER INFORMATION CONTACT:
Theodore Katz, MPA, Designated
Federal Officer, NIOSH, CDC, 1600
Clifton Road, Mailstop E-20, Atlanta,
Georgia 30333, Telephone (513) 533-
6800, Toll Free 1(800) CDC-INFO,
Email ocas@cdc.gov.

SUPPLEMENTARY INFORMATION:

Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that
have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).

In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
rechartered on March 22, 2016,

pursuant to Executive Order 13708, and will expire on September 30, 2017.

Purpose: The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. SPR was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction. SPR is responsible for overseeing, tracking, and participating in the reviews of all procedures used in the dose reconstruction process by the NIOSH Division of Compensation Analysis and Support (DCAS) and its dose reconstruction contractor (Oak Ridge Associated Universities—ORAU).

Matters to be Considered: The agenda will include discussions on the following dose reconstruction procedures: DCAS Program Evaluation Report 59 (addressing dose reconstructions at the Norton Company, Worcester MA); DCAS Report 5: Alternative Dissolution Models for Insoluble Plutonium 238; Outstanding Findings of Prior Subcommittee Reviews; and DCAS Procedures Not Yet Reviewed. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2017–21046 Filed 9–29–17; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2017–D–5140]

Display Devices for Diagnostic Radiology; Guidance for Industry and Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of the guidance entitled “Display Devices for Diagnostic Radiology.” This guidance document provides recommendations for the types of information you should provide in your premarket notification submission (510(k)) for display devices intended for diagnostic radiology with the assigned product code PGY. This guidance replaces a previously issued final guidance entitled “Display Accessories for Full-Field Digital Mammography Systems-Premarket Notification (510(k)) Submissions” issued on May 30, 2008.

DATES: The announcement of the guidance is published in the **Federal Register** on October 2, 2017.

ADDRESSES: You may submit either electronic or written comments on Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the

manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2017–D–5140 for “Display Devices for Diagnostic Radiology” comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://>